董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dirk Thye | 男 | Chief Executive Officer and Chief Medical Officer and Director | 56 | 249.36万美元 | 2.48 | 2026-06-11 |
| Christopher J. Senner | 男 | Director | 58 | 7.90万美元 | 0.13 | 2026-06-11 |
| David A. Lamond | 男 | Chairperson of the Board and Director | 51 | 9.81万美元 | 2.19 | 2026-06-11 |
| June Bray | 女 | Director | 70 | 7.12万美元 | 未持股 | 2026-06-11 |
| Brigette Roberts | 女 | Chief of Corporate Affairs and Director | 50 | 未披露 | 未持股 | 2026-06-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dirk Thye | 男 | Chief Executive Officer and Chief Medical Officer and Director | 56 | 249.36万美元 | 2.48 | 2026-06-11 |
| Charles Ryan | 男 | President | 61 | 114.41万美元 | 0.37 | 2026-06-11 |
| Brendan Hannah | 男 | Chief Business Officer and Chief Compliance Officer and Chief Operating Officer | 40 | 126.31万美元 | 0.78 | 2026-06-11 |
| Brigette Roberts | 女 | Chief of Corporate Affairs and Director | 50 | 未披露 | 未持股 | 2026-06-11 |
董事简历
中英对照 | 中文 | 英文- Dirk Thye
-
Dirk Thye，2014年7月加入本公司，担任首席医学官。2005年以来，他是生物制药私营公司Cerexa的创始人之一，该公司在2007年被Forest Laboratories, Inc收购。他在Forest Laboratories, Inc担任过一些职务，于2011年以总裁身份结束任职。加入Cerexa之前，2001-2005，他是生物制药公司Peninsula Pharmaceuticals的创始人、临床开发高级副总裁。另外，他曾在抗感染领域的一些公司担任董事或科学顾问委员会成员。他在University of California, Berkeley获得分子生物学士学位，在 University of California, Los Angeles获得医学博士学位，在Stanford University的内科完成驻院实习。
Dirk Thye has served as Quince Therapeutics, Inc.'s Chief Executive Officer and member of the Board of Directors since May 2022 and Chief Medical Officer since January 2024. Prior to joining Quince Therapeutics, Inc., he served as the Chief Executive Officer of Novosteo Inc. from September 2021 to May 2022. Previously, Dr. Thye was the Executive Chairman of Geom Therapeutics, Inc. from January 2016 to July 2020 and the Chief Executive Officer of Agenovir Corporation from September 2016 to January 2018. Dr. Thye holds a M.D. from the University of California, Los Angeles and a B.A. in Molecular Biology from the University of California, Berkeley. - Dirk Thye，2014年7月加入本公司，担任首席医学官。2005年以来，他是生物制药私营公司Cerexa的创始人之一，该公司在2007年被Forest Laboratories, Inc收购。他在Forest Laboratories, Inc担任过一些职务，于2011年以总裁身份结束任职。加入Cerexa之前，2001-2005，他是生物制药公司Peninsula Pharmaceuticals的创始人、临床开发高级副总裁。另外，他曾在抗感染领域的一些公司担任董事或科学顾问委员会成员。他在University of California, Berkeley获得分子生物学士学位，在 University of California, Los Angeles获得医学博士学位，在Stanford University的内科完成驻院实习。
- Dirk Thye has served as Quince Therapeutics, Inc.'s Chief Executive Officer and member of the Board of Directors since May 2022 and Chief Medical Officer since January 2024. Prior to joining Quince Therapeutics, Inc., he served as the Chief Executive Officer of Novosteo Inc. from September 2021 to May 2022. Previously, Dr. Thye was the Executive Chairman of Geom Therapeutics, Inc. from January 2016 to July 2020 and the Chief Executive Officer of Agenovir Corporation from September 2016 to January 2018. Dr. Thye holds a M.D. from the University of California, Los Angeles and a B.A. in Molecular Biology from the University of California, Berkeley.
- Christopher J. Senner
-
Christopher J. Senner， 曾一直担任执行副总裁兼首席财务官、首席财务官兼首席会计官（由适用的证券法定义）（2015年7月以来）。加入Exelixis公司之前，他曾担任Gilead Sciences, Inc.（生物制药公司）的公司财务副总裁（2010年3月至2015年7月），在那里他曾负责管理员职位、运营财务计划和分析，包括研发、制造、商业运作、税收和财政计划。他此前曾任职Wyeth公司18年，担任多种财务职务，并不断被提拔，最近担任Wyeth公司的美国制药企业和生物制药业务单元的首席财务官。他持有Bentley College的财务学士学位。此前披露指示他是一位注册会计师不准确是由于相关文件中的行政错误。他不是一个注册会计师。
Christopher J. Senner has served on Quince Therapeutics, Inc.'s board of directors since March 2019. Mr. Senner has served as Executive Vice President and Chief Financial Officer for Exelixis, Inc. since 2015. Prior to joining Exelixis, Inc., Mr. Senner served as Vice President, Corporate Finance for Gilead Sciences, Inc., a biopharmaceutical company, from 2010 to 2015, where he was accountable for controllership, tax, treasury and corporate and operational financial planning. Mr. Senner previously spent 18 years at Wyeth, a pharmaceutical company acquired by Pfizer Inc. in 2009, in a variety of financial roles with increasing responsibility, most notably as Chief Financial Officer of Wyeth's United States pharmaceuticals business and the BioPharma business unit. Mr. Senner holds an undergraduate degree in Finance from Bentley College. - Christopher J. Senner， 曾一直担任执行副总裁兼首席财务官、首席财务官兼首席会计官（由适用的证券法定义）（2015年7月以来）。加入Exelixis公司之前，他曾担任Gilead Sciences, Inc.（生物制药公司）的公司财务副总裁（2010年3月至2015年7月），在那里他曾负责管理员职位、运营财务计划和分析，包括研发、制造、商业运作、税收和财政计划。他此前曾任职Wyeth公司18年，担任多种财务职务，并不断被提拔，最近担任Wyeth公司的美国制药企业和生物制药业务单元的首席财务官。他持有Bentley College的财务学士学位。此前披露指示他是一位注册会计师不准确是由于相关文件中的行政错误。他不是一个注册会计师。
- Christopher J. Senner has served on Quince Therapeutics, Inc.'s board of directors since March 2019. Mr. Senner has served as Executive Vice President and Chief Financial Officer for Exelixis, Inc. since 2015. Prior to joining Exelixis, Inc., Mr. Senner served as Vice President, Corporate Finance for Gilead Sciences, Inc., a biopharmaceutical company, from 2010 to 2015, where he was accountable for controllership, tax, treasury and corporate and operational financial planning. Mr. Senner previously spent 18 years at Wyeth, a pharmaceutical company acquired by Pfizer Inc. in 2009, in a variety of financial roles with increasing responsibility, most notably as Chief Financial Officer of Wyeth's United States pharmaceuticals business and the BioPharma business unit. Mr. Senner holds an undergraduate degree in Finance from Bentley College.
- David A. Lamond
-
David Lamond自2020年2月以来一直担任我们的董事会成员。自2016年4月起，Lamond先生一直担任投资公司En Pointe LLC的总裁。2011年11月至2016年6月，他担任对冲基金Lamond Capital Partners LLC的总裁，首席执行官和首席投资官。他自2018年9月起担任生物技术公司Applied Molecular TransportInc.的董事会成员，自2020年2月起担任医疗器械公司Inquis Clinical Research Ltd.的董事会成员，自2015年12月起担任生物制药公司Cortexyme，Inc.的董事会成员，自2015年12月起担任基因治疗公司Genelpis的董事会成员，自2019年8月起担任Arrinex，Inc.（一家医疗设备公司，现为史赛克公司的子公司）的董事会成员。Lamond先生拥有杜克大学（Duke University）历史学学士学位和杜克法学院（Duke Law School）法学博士学位。
David A. Lamond has served on Quince Therapeutics, Inc.'s board of directors since December 2015. Mr. Lamond has served as the president of En Pointe LLC, an investment firm, since 2016. He served as the President, Chief Executive Officer and Chief Investment Officer of Lamond Capital Partners LLC from 2011 to 2016. He also serves on the board of directors of EG 427, a biotechnology company, Inquis Medical, a medical device company and Windfall Data, an analytics company. He previously served on the board of Applied Molecular Transport, a biotechnology company, and Arrinex, a medical device company until its acquisition by Stryker Corporation in February 2019. Mr. Lamond holds a B.A. in History from Duke University and a J.D. from Duke Law School. - David Lamond自2020年2月以来一直担任我们的董事会成员。自2016年4月起，Lamond先生一直担任投资公司En Pointe LLC的总裁。2011年11月至2016年6月，他担任对冲基金Lamond Capital Partners LLC的总裁，首席执行官和首席投资官。他自2018年9月起担任生物技术公司Applied Molecular TransportInc.的董事会成员，自2020年2月起担任医疗器械公司Inquis Clinical Research Ltd.的董事会成员，自2015年12月起担任生物制药公司Cortexyme，Inc.的董事会成员，自2015年12月起担任基因治疗公司Genelpis的董事会成员，自2019年8月起担任Arrinex，Inc.（一家医疗设备公司，现为史赛克公司的子公司）的董事会成员。Lamond先生拥有杜克大学（Duke University）历史学学士学位和杜克法学院（Duke Law School）法学博士学位。
- David A. Lamond has served on Quince Therapeutics, Inc.'s board of directors since December 2015. Mr. Lamond has served as the president of En Pointe LLC, an investment firm, since 2016. He served as the President, Chief Executive Officer and Chief Investment Officer of Lamond Capital Partners LLC from 2011 to 2016. He also serves on the board of directors of EG 427, a biotechnology company, Inquis Medical, a medical device company and Windfall Data, an analytics company. He previously served on the board of Applied Molecular Transport, a biotechnology company, and Arrinex, a medical device company until its acquisition by Stryker Corporation in February 2019. Mr. Lamond holds a B.A. in History from Duke University and a J.D. from Duke Law School.
- June Bray
-
琼·布雷，自2021年3月起担任Bioxcel Therapeutics公司董事。她曾于2008年至2020年担任制药公司眼力健制药公司全球监管事务和医学写作高级副总裁，负责所有治疗领域的开发项目和生命周期管理的全球监管战略。从2006年到2008年，布雷女士担任Organon & Co.（在与默沙东合并之前）的监管事务副总裁，领导部门负责开发和销售产品的监管活动。从1980年到2006年，布雷女士在Berlex Laboratories，Inc.担任过各种职务，最近在2003年到2006年担任专门治疗/肿瘤学全球监管事务副总裁。布雷女士自2022年6月起担任Quince Therapeutics，Inc.董事会成员。布雷拥有费尔利·迪金森大学的工商管理硕士学位和罗德岛大学的学士学位。
June Bray served on Quince Therapeutics, Inc.'s board of directors from June 2022 to January 2026, and rejoined Quince Therapeutics, Inc.'s board on April 21, 2026. Ms. Bray has been a member of the board of directors of BioXcel Therapeutics, Inc. since March 2021 and Travecta Therapeutics from October 2021 to October 2022. Ms. Bray has been a member of the advisory board of Formation Bio, a technology driven pharmaceutical company, since 2022. Previously, she served as Senior Vice President, Global Regulatory Affairs and Medical Writing at Allergan, where she was responsible for regulatory strategies on development projects and lifecycle management in all therapeutic areas, including psychiatry and neurology. Ms. Bray also served as Vice President, Regulatory Affairs at Organon (now Merck), where she led regulatory activities for development and marketed products. Earlier in her career, Ms. Bray held numerous roles of increasing responsibility over a 25 year period at Berlex Laboratories, Inc. (now Bayer HealthCare Pharmaceuticals). She began her pharmaceutical career in sterile manufacturing at Hoechst Roussel Pharmaceuticals (now Sanofi Aventis). Ms. Bray holds a B.S. in Pharmacy from the University of Rhode Island and an MBA in Pharmaceutical Marketing from Fairleigh Dickinson University. - 琼·布雷，自2021年3月起担任Bioxcel Therapeutics公司董事。她曾于2008年至2020年担任制药公司眼力健制药公司全球监管事务和医学写作高级副总裁，负责所有治疗领域的开发项目和生命周期管理的全球监管战略。从2006年到2008年，布雷女士担任Organon & Co.（在与默沙东合并之前）的监管事务副总裁，领导部门负责开发和销售产品的监管活动。从1980年到2006年，布雷女士在Berlex Laboratories，Inc.担任过各种职务，最近在2003年到2006年担任专门治疗/肿瘤学全球监管事务副总裁。布雷女士自2022年6月起担任Quince Therapeutics，Inc.董事会成员。布雷拥有费尔利·迪金森大学的工商管理硕士学位和罗德岛大学的学士学位。
- June Bray served on Quince Therapeutics, Inc.'s board of directors from June 2022 to January 2026, and rejoined Quince Therapeutics, Inc.'s board on April 21, 2026. Ms. Bray has been a member of the board of directors of BioXcel Therapeutics, Inc. since March 2021 and Travecta Therapeutics from October 2021 to October 2022. Ms. Bray has been a member of the advisory board of Formation Bio, a technology driven pharmaceutical company, since 2022. Previously, she served as Senior Vice President, Global Regulatory Affairs and Medical Writing at Allergan, where she was responsible for regulatory strategies on development projects and lifecycle management in all therapeutic areas, including psychiatry and neurology. Ms. Bray also served as Vice President, Regulatory Affairs at Organon (now Merck), where she led regulatory activities for development and marketed products. Earlier in her career, Ms. Bray held numerous roles of increasing responsibility over a 25 year period at Berlex Laboratories, Inc. (now Bayer HealthCare Pharmaceuticals). She began her pharmaceutical career in sterile manufacturing at Hoechst Roussel Pharmaceuticals (now Sanofi Aventis). Ms. Bray holds a B.S. in Pharmacy from the University of Rhode Island and an MBA in Pharmaceutical Marketing from Fairleigh Dickinson University.
- Brigette Roberts
-
Brigette Roberts自2026年5月起担任公司首席公司事务官兼董事会成员。在此之前，她于2021年5月至2026年5月期间担任Orphai Therapeutics，Inc.（“Orphai”）的首席执行官和董事会成员，在此之前，她于2021年2月至2021年5月期间担任Orphai的首席医疗官。在Orphai任职期间，罗伯茨博士建立了以LAM 001为中心的差异化肺部专营权，LAM 001是一种用于肺血管和纤维化肺部疾病的雷帕霉素吸入制剂，启动了LAM 001的两项2期研究，获得了LAM 001跨多个适应症的美国和欧盟孤儿药指定，并筹集了超过4500万美元的新私人投资。在加入Orphai之前，Roberts博士于2017年至2021年1月在Fortress Biotech担任常驻企业家，在那里她发现了新的资产，可以转型成为新的生物技术公司。在此之前，罗伯茨博士曾在CDP资本、Angel Lane Principal Strategies、YYC Capital（她创立的公司）、Third Point，LLC和DKR Capital担任超过15年的医疗保健投资者和投资组合经理。Roberts博士还于2005年12月至2007年2月期间担任Ligand制药公司的董事。罗伯茨博士拥有哈佛大学物理和化学学士学位和纽约大学医学博士学位。
Brigette Roberts has served as the Company's Chief Corporate Affairs Officer and member of the Board since May 2026. Prior to that, she served as the Chief Executive Officer and member of the Board of Directors of Orphai Therapeutics, Inc. ("Orphai") from May 2021 until May 2026, and prior to that she served as the Chief Medical Officer of Orphai from February 2021 until May 2021. During her time at Orphai, Dr. Roberts built a differentiated pulmonary franchise centered on LAM 001, an inhaled formulation of rapamycin for pulmonary vascular and fibrotic lung diseases, initiated two Phase 2 studies of LAM 001, secured United States and European Union orphan drug designations for LAM 001 across multiple indications and raised more than $45 million in new private investment. Prior to Orphai, Dr. Roberts served as an Entrepreneur in Residence at Fortress Biotech from 2017 to January 2021 where she identified new assets to spin into new biotechnology companies. Prior to that, Dr. Roberts spent over 15 years as a healthcare investor and portfolio manager including at CDP Capital, Angel Lane Principal Strategies, YYC Capital (which she founded), Third Point, LLC and DKR Capital. Dr. Roberts also served as a director of Ligand Pharmaceuticals from December 2005 to February 2007. Dr. Roberts holds a B.A. in Physics and Chemistry from Harvard University and an M.D. from New York University. - Brigette Roberts自2026年5月起担任公司首席公司事务官兼董事会成员。在此之前，她于2021年5月至2026年5月期间担任Orphai Therapeutics，Inc.（“Orphai”）的首席执行官和董事会成员，在此之前，她于2021年2月至2021年5月期间担任Orphai的首席医疗官。在Orphai任职期间，罗伯茨博士建立了以LAM 001为中心的差异化肺部专营权，LAM 001是一种用于肺血管和纤维化肺部疾病的雷帕霉素吸入制剂，启动了LAM 001的两项2期研究，获得了LAM 001跨多个适应症的美国和欧盟孤儿药指定，并筹集了超过4500万美元的新私人投资。在加入Orphai之前，Roberts博士于2017年至2021年1月在Fortress Biotech担任常驻企业家，在那里她发现了新的资产，可以转型成为新的生物技术公司。在此之前，罗伯茨博士曾在CDP资本、Angel Lane Principal Strategies、YYC Capital（她创立的公司）、Third Point，LLC和DKR Capital担任超过15年的医疗保健投资者和投资组合经理。Roberts博士还于2005年12月至2007年2月期间担任Ligand制药公司的董事。罗伯茨博士拥有哈佛大学物理和化学学士学位和纽约大学医学博士学位。
- Brigette Roberts has served as the Company's Chief Corporate Affairs Officer and member of the Board since May 2026. Prior to that, she served as the Chief Executive Officer and member of the Board of Directors of Orphai Therapeutics, Inc. ("Orphai") from May 2021 until May 2026, and prior to that she served as the Chief Medical Officer of Orphai from February 2021 until May 2021. During her time at Orphai, Dr. Roberts built a differentiated pulmonary franchise centered on LAM 001, an inhaled formulation of rapamycin for pulmonary vascular and fibrotic lung diseases, initiated two Phase 2 studies of LAM 001, secured United States and European Union orphan drug designations for LAM 001 across multiple indications and raised more than $45 million in new private investment. Prior to Orphai, Dr. Roberts served as an Entrepreneur in Residence at Fortress Biotech from 2017 to January 2021 where she identified new assets to spin into new biotechnology companies. Prior to that, Dr. Roberts spent over 15 years as a healthcare investor and portfolio manager including at CDP Capital, Angel Lane Principal Strategies, YYC Capital (which she founded), Third Point, LLC and DKR Capital. Dr. Roberts also served as a director of Ligand Pharmaceuticals from December 2005 to February 2007. Dr. Roberts holds a B.A. in Physics and Chemistry from Harvard University and an M.D. from New York University.
高管简历
中英对照 | 中文 | 英文- Dirk Thye
Dirk Thye，2014年7月加入本公司，担任首席医学官。2005年以来，他是生物制药私营公司Cerexa的创始人之一，该公司在2007年被Forest Laboratories, Inc收购。他在Forest Laboratories, Inc担任过一些职务，于2011年以总裁身份结束任职。加入Cerexa之前，2001-2005，他是生物制药公司Peninsula Pharmaceuticals的创始人、临床开发高级副总裁。另外，他曾在抗感染领域的一些公司担任董事或科学顾问委员会成员。他在University of California, Berkeley获得分子生物学士学位，在 University of California, Los Angeles获得医学博士学位，在Stanford University的内科完成驻院实习。
Dirk Thye has served as Quince Therapeutics, Inc.'s Chief Executive Officer and member of the Board of Directors since May 2022 and Chief Medical Officer since January 2024. Prior to joining Quince Therapeutics, Inc., he served as the Chief Executive Officer of Novosteo Inc. from September 2021 to May 2022. Previously, Dr. Thye was the Executive Chairman of Geom Therapeutics, Inc. from January 2016 to July 2020 and the Chief Executive Officer of Agenovir Corporation from September 2016 to January 2018. Dr. Thye holds a M.D. from the University of California, Los Angeles and a B.A. in Molecular Biology from the University of California, Berkeley.- Dirk Thye，2014年7月加入本公司，担任首席医学官。2005年以来，他是生物制药私营公司Cerexa的创始人之一，该公司在2007年被Forest Laboratories, Inc收购。他在Forest Laboratories, Inc担任过一些职务，于2011年以总裁身份结束任职。加入Cerexa之前，2001-2005，他是生物制药公司Peninsula Pharmaceuticals的创始人、临床开发高级副总裁。另外，他曾在抗感染领域的一些公司担任董事或科学顾问委员会成员。他在University of California, Berkeley获得分子生物学士学位，在 University of California, Los Angeles获得医学博士学位，在Stanford University的内科完成驻院实习。
- Dirk Thye has served as Quince Therapeutics, Inc.'s Chief Executive Officer and member of the Board of Directors since May 2022 and Chief Medical Officer since January 2024. Prior to joining Quince Therapeutics, Inc., he served as the Chief Executive Officer of Novosteo Inc. from September 2021 to May 2022. Previously, Dr. Thye was the Executive Chairman of Geom Therapeutics, Inc. from January 2016 to July 2020 and the Chief Executive Officer of Agenovir Corporation from September 2016 to January 2018. Dr. Thye holds a M.D. from the University of California, Los Angeles and a B.A. in Molecular Biology from the University of California, Berkeley.
- Charles Ryan
Charles Ryan自2023年9月起担任Quince Therapeutics，Inc.总裁。2026年2月，Ryan博士成为Polaryx Therapeutics，Inc.的董事会成员。2021年5月至2022年10月，Ryan博士担任Travecta Therapeutics的总裁、首席执行官和董事长，该公司是一家开创严重神经系统疾病变革性治疗的私营生物制药公司。2017年12月至2022年12月，他担任Neurotrope, Inc.的首席执行官和董事，该公司是一家临床阶段的生物制药公司，为神经退行性疾病和发育障碍开发靶向、新型再生疗法。在此之前，他曾在Forest Laboratories（现为艾伯维）担任高级副总裁兼首席知识产权法律顾问超过10年，在那里他管理了跨越CNS、心血管、胃肠道、呼吸和抗感染治疗领域的多个知识产权产业。他还与商业和开发团队以及Forest的商业开发团队密切合作。Ryan博士拥有Western New England大学法学博士学位、石溪大学口腔生物学和病理学博士学位以及伍斯特学院化学学士学位。他是纽约州律师协会会员，是美国专利商标局的专利从业人员。
Charles Ryan has served as Quince Therapeutics, Inc.'s President since September 2023. In February 2026, Dr. Ryan became a member of the board of directors of Polaryx Therapeutics, Inc. From May 2021 to October 2022, Dr. Ryan served as President, Chief Executive Officer, and Chairman of Travecta Therapeutics, a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions and from December 2017 to December 2022, he served as Chief Executive Officer and Director of Neurotrope, Inc., a clinical stage biopharmaceutical company developing targeted, novel regenerative therapeutics for neurodegenerative diseases and developmental disorders. Prior to that, he served as Senior Vice President and Chief Intellectual Property Counsel at Forest Laboratories (now AbbVie) for more than 10 years where he managed several intellectual property estates spanning CNS, cardiovascular, gastrointestinal, respiratory, and anti infective therapeutic areas. He also worked closely with the commercial and development teams, as well as the business development teams at Forest. Dr. Ryan holds a J.D. from Western New England University, a Ph.D. in Oral Biology and Pathology from Stony Brook University, and a B.A. in Chemistry from The College of Wooster. He is a member of the New York State Bar and is a patent practitioner of the U.S. Patent and Trademark Office.- Charles Ryan自2023年9月起担任Quince Therapeutics，Inc.总裁。2026年2月，Ryan博士成为Polaryx Therapeutics，Inc.的董事会成员。2021年5月至2022年10月，Ryan博士担任Travecta Therapeutics的总裁、首席执行官和董事长，该公司是一家开创严重神经系统疾病变革性治疗的私营生物制药公司。2017年12月至2022年12月，他担任Neurotrope, Inc.的首席执行官和董事，该公司是一家临床阶段的生物制药公司，为神经退行性疾病和发育障碍开发靶向、新型再生疗法。在此之前，他曾在Forest Laboratories（现为艾伯维）担任高级副总裁兼首席知识产权法律顾问超过10年，在那里他管理了跨越CNS、心血管、胃肠道、呼吸和抗感染治疗领域的多个知识产权产业。他还与商业和开发团队以及Forest的商业开发团队密切合作。Ryan博士拥有Western New England大学法学博士学位、石溪大学口腔生物学和病理学博士学位以及伍斯特学院化学学士学位。他是纽约州律师协会会员，是美国专利商标局的专利从业人员。
- Charles Ryan has served as Quince Therapeutics, Inc.'s President since September 2023. In February 2026, Dr. Ryan became a member of the board of directors of Polaryx Therapeutics, Inc. From May 2021 to October 2022, Dr. Ryan served as President, Chief Executive Officer, and Chairman of Travecta Therapeutics, a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions and from December 2017 to December 2022, he served as Chief Executive Officer and Director of Neurotrope, Inc., a clinical stage biopharmaceutical company developing targeted, novel regenerative therapeutics for neurodegenerative diseases and developmental disorders. Prior to that, he served as Senior Vice President and Chief Intellectual Property Counsel at Forest Laboratories (now AbbVie) for more than 10 years where he managed several intellectual property estates spanning CNS, cardiovascular, gastrointestinal, respiratory, and anti infective therapeutic areas. He also worked closely with the commercial and development teams, as well as the business development teams at Forest. Dr. Ryan holds a J.D. from Western New England University, a Ph.D. in Oral Biology and Pathology from Stony Brook University, and a B.A. in Chemistry from The College of Wooster. He is a member of the New York State Bar and is a patent practitioner of the U.S. Patent and Trademark Office.
- Brendan Hannah
Brendan Hannah，于2021年11月至2022年5月担任生物制药公司Novosteo Inc.的首席运营官。此前，自2019年1月至2021年10月，Hannah先生担任生物制药公司Neuroptika，Inc.的首席商务官，并于2017年1月至2020年3月担任生物制药公司Geom Therapeutics的运营和战略副总裁。Hannah先生拥有加州大学洛杉矶安德森管理学院的工商管理硕士学位和科罗拉多学院的经济学学士学位。
Brendan Hannah has served as Quince Therapeutics, Inc.'s Chief Business Officer since May 2022 and was appointed as Quince Therapeutics, Inc.'s Chief Compliance Officer in March 2023 and Quince Therapeutics, Inc.'s Chief Operating Officer in October 2023. Previously, Mr. Hannah served as the Chief Operating Officer of Novosteo Inc., a biopharmaceutical company, from November 2021 to May 2022. Previously, from January 2019 to October 2021, Mr. Hannah was the Chief Business Officer of Neuroptika, Inc., a biopharmaceutical company, and from January 2017 to March 2020, the Vice President of Operations and Strategy of Geom Therapeutics, a biopharmaceutical company. Mr. Hannah holds an M.B.A. from the University of California, Los Angeles Anderson School of Management and a B.A. in Economics from Colorado College.- Brendan Hannah，于2021年11月至2022年5月担任生物制药公司Novosteo Inc.的首席运营官。此前，自2019年1月至2021年10月，Hannah先生担任生物制药公司Neuroptika，Inc.的首席商务官，并于2017年1月至2020年3月担任生物制药公司Geom Therapeutics的运营和战略副总裁。Hannah先生拥有加州大学洛杉矶安德森管理学院的工商管理硕士学位和科罗拉多学院的经济学学士学位。
- Brendan Hannah has served as Quince Therapeutics, Inc.'s Chief Business Officer since May 2022 and was appointed as Quince Therapeutics, Inc.'s Chief Compliance Officer in March 2023 and Quince Therapeutics, Inc.'s Chief Operating Officer in October 2023. Previously, Mr. Hannah served as the Chief Operating Officer of Novosteo Inc., a biopharmaceutical company, from November 2021 to May 2022. Previously, from January 2019 to October 2021, Mr. Hannah was the Chief Business Officer of Neuroptika, Inc., a biopharmaceutical company, and from January 2017 to March 2020, the Vice President of Operations and Strategy of Geom Therapeutics, a biopharmaceutical company. Mr. Hannah holds an M.B.A. from the University of California, Los Angeles Anderson School of Management and a B.A. in Economics from Colorado College.
- Brigette Roberts
Brigette Roberts自2026年5月起担任公司首席公司事务官兼董事会成员。在此之前，她于2021年5月至2026年5月期间担任Orphai Therapeutics，Inc.（“Orphai”）的首席执行官和董事会成员，在此之前，她于2021年2月至2021年5月期间担任Orphai的首席医疗官。在Orphai任职期间，罗伯茨博士建立了以LAM 001为中心的差异化肺部专营权，LAM 001是一种用于肺血管和纤维化肺部疾病的雷帕霉素吸入制剂，启动了LAM 001的两项2期研究，获得了LAM 001跨多个适应症的美国和欧盟孤儿药指定，并筹集了超过4500万美元的新私人投资。在加入Orphai之前，Roberts博士于2017年至2021年1月在Fortress Biotech担任常驻企业家，在那里她发现了新的资产，可以转型成为新的生物技术公司。在此之前，罗伯茨博士曾在CDP资本、Angel Lane Principal Strategies、YYC Capital（她创立的公司）、Third Point，LLC和DKR Capital担任超过15年的医疗保健投资者和投资组合经理。Roberts博士还于2005年12月至2007年2月期间担任Ligand制药公司的董事。罗伯茨博士拥有哈佛大学物理和化学学士学位和纽约大学医学博士学位。
Brigette Roberts has served as the Company's Chief Corporate Affairs Officer and member of the Board since May 2026. Prior to that, she served as the Chief Executive Officer and member of the Board of Directors of Orphai Therapeutics, Inc. ("Orphai") from May 2021 until May 2026, and prior to that she served as the Chief Medical Officer of Orphai from February 2021 until May 2021. During her time at Orphai, Dr. Roberts built a differentiated pulmonary franchise centered on LAM 001, an inhaled formulation of rapamycin for pulmonary vascular and fibrotic lung diseases, initiated two Phase 2 studies of LAM 001, secured United States and European Union orphan drug designations for LAM 001 across multiple indications and raised more than $45 million in new private investment. Prior to Orphai, Dr. Roberts served as an Entrepreneur in Residence at Fortress Biotech from 2017 to January 2021 where she identified new assets to spin into new biotechnology companies. Prior to that, Dr. Roberts spent over 15 years as a healthcare investor and portfolio manager including at CDP Capital, Angel Lane Principal Strategies, YYC Capital (which she founded), Third Point, LLC and DKR Capital. Dr. Roberts also served as a director of Ligand Pharmaceuticals from December 2005 to February 2007. Dr. Roberts holds a B.A. in Physics and Chemistry from Harvard University and an M.D. from New York University.- Brigette Roberts自2026年5月起担任公司首席公司事务官兼董事会成员。在此之前，她于2021年5月至2026年5月期间担任Orphai Therapeutics，Inc.（“Orphai”）的首席执行官和董事会成员，在此之前，她于2021年2月至2021年5月期间担任Orphai的首席医疗官。在Orphai任职期间，罗伯茨博士建立了以LAM 001为中心的差异化肺部专营权，LAM 001是一种用于肺血管和纤维化肺部疾病的雷帕霉素吸入制剂，启动了LAM 001的两项2期研究，获得了LAM 001跨多个适应症的美国和欧盟孤儿药指定，并筹集了超过4500万美元的新私人投资。在加入Orphai之前，Roberts博士于2017年至2021年1月在Fortress Biotech担任常驻企业家，在那里她发现了新的资产，可以转型成为新的生物技术公司。在此之前，罗伯茨博士曾在CDP资本、Angel Lane Principal Strategies、YYC Capital（她创立的公司）、Third Point，LLC和DKR Capital担任超过15年的医疗保健投资者和投资组合经理。Roberts博士还于2005年12月至2007年2月期间担任Ligand制药公司的董事。罗伯茨博士拥有哈佛大学物理和化学学士学位和纽约大学医学博士学位。
- Brigette Roberts has served as the Company's Chief Corporate Affairs Officer and member of the Board since May 2026. Prior to that, she served as the Chief Executive Officer and member of the Board of Directors of Orphai Therapeutics, Inc. ("Orphai") from May 2021 until May 2026, and prior to that she served as the Chief Medical Officer of Orphai from February 2021 until May 2021. During her time at Orphai, Dr. Roberts built a differentiated pulmonary franchise centered on LAM 001, an inhaled formulation of rapamycin for pulmonary vascular and fibrotic lung diseases, initiated two Phase 2 studies of LAM 001, secured United States and European Union orphan drug designations for LAM 001 across multiple indications and raised more than $45 million in new private investment. Prior to Orphai, Dr. Roberts served as an Entrepreneur in Residence at Fortress Biotech from 2017 to January 2021 where she identified new assets to spin into new biotechnology companies. Prior to that, Dr. Roberts spent over 15 years as a healthcare investor and portfolio manager including at CDP Capital, Angel Lane Principal Strategies, YYC Capital (which she founded), Third Point, LLC and DKR Capital. Dr. Roberts also served as a director of Ligand Pharmaceuticals from December 2005 to February 2007. Dr. Roberts holds a B.A. in Physics and Chemistry from Harvard University and an M.D. from New York University.